Hapoalim Securities downgrades XenoPort (Nasdaq: XNPT) from Buy to Sell. Price target $10.

Hapoalim anayst says, "The FDA rejected XenoPort ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE